EGFR and cancer: Cancer cells harboring the KRAS G12C mutation entered a quiescent state, in which some of the cells died, while others were able to overcome this inhibition through the synthesis of new KRAS G12C proteins that can be rapidly activated through the upstream effectors EGFR and AURKA [40] (Fig. 6).